326 related articles for article (PubMed ID: 3355609)
1. Influence of apolipoprotein E polymorphism on plasma lipid and apolipoprotein levels, and clinical characteristics of type III hyperlipoproteinemia due to apolipoprotein E phenotype E2/2 in Japan.
Kobori S; Nakamura N; Uzawa H; Shichiri M
Atherosclerosis; 1988 Jan; 69(1):81-8. PubMed ID: 3355609
[TBL] [Abstract][Full Text] [Related]
2. Detailed analysis of serum lipids and lipoproteins from Japanese type III hyperlipoproteinemia with apolipoprotein E2/2 phenotype.
Todo Y; Kobayashi J; Higashikata T; Kawashiri M; Nohara A; Inazu A; Koizumi J; Mabuchi H
Clin Chim Acta; 2004 Oct; 348(1-2):35-40. PubMed ID: 15369733
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein epsilon 2/3 genotype and type III hyperlipoproteinemia among Taiwanese.
Lin HP; Kao JT
Clin Chim Acta; 2003 Apr; 330(1-2):173-8. PubMed ID: 12636937
[TBL] [Abstract][Full Text] [Related]
4. Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3.
Kobayashi T; Homma Y
J Clin Pharmacol; 2001 Oct; 41(10):1055-8. PubMed ID: 11583472
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein E2(Arg158----Cys) frequency in a hyperlipidemic French-Canadian population of apolipoprotein E2/2 subjects. Determination by synthetic oligonucleotide probes.
Weisgraber KH; Newhouse YM; Taylor JM; Tuan B; Nestruck AC; Davignon J; Mahley RW
Arteriosclerosis; 1989; 9(1):50-7. PubMed ID: 2912421
[TBL] [Abstract][Full Text] [Related]
6. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2.
Breslow JL; Zannis VI; SanGiacomo TR; Third JL; Tracy T; Glueck CJ
J Lipid Res; 1982 Nov; 23(8):1224-35. PubMed ID: 7175379
[TBL] [Abstract][Full Text] [Related]
7. Lathosterol level in plasma is elevated in type III hyperlipoproteinemia, but not in non-type III subjects with apolipoprotein E2/2 phenotype, nor in type IIa or IIb hyperlipoproteinemia.
Kempen HJ; Gevers Leuven JA; van der Voort HA; de Knijff P; Havekes L
Metabolism; 1991 Mar; 40(3):231-5. PubMed ID: 2000034
[TBL] [Abstract][Full Text] [Related]
8. Influence of apolipoprotein E polymorphism on the tracking of childhood levels of serum lipids and apolipoproteins over a 6-year period. The Bogalusa Heart Study.
Srinivasan SR; Ehnholm C; Wattigney WA; Berenson GS
Atherosclerosis; 1996 Nov; 127(1):73-9. PubMed ID: 9006807
[TBL] [Abstract][Full Text] [Related]
9. Reciprocal effects of apolipoprotein E alleles (epsilon 2 and epsilon 4) on plasma lipid levels in normolipidemic subjects.
Eto M; Watanabe K; Ishii K
Clin Genet; 1986 Jun; 29(6):477-84. PubMed ID: 3461894
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia.
Feussner G; Albanese M; Mann WA; Valencia A; Schuster H
Eur J Clin Invest; 1996 Jan; 26(1):13-23. PubMed ID: 8682150
[TBL] [Abstract][Full Text] [Related]
11. Cord blood apolipoprotein-E genotype distribution and plasma lipid indices in newborns of different ethnicity.
Brouwer DA; Mulder H; Fokkens B; Ramsewak S; Muskiet FA; Ramdath DD
Ann Hum Biol; 2000; 27(4):367-75. PubMed ID: 10942344
[TBL] [Abstract][Full Text] [Related]
12. Remnant-like lipoprotein particles in type 2 diabetic patients with apolipoprotein E3/3 and apolipoprotein E2 genotypes.
Saito M; Eto M; Kaku K
Metabolism; 2002 Aug; 51(8):964-9. PubMed ID: 12145767
[TBL] [Abstract][Full Text] [Related]
13. Relationship between apolipoprotein E polymorphism, menopausal symptoms, and serum lipids during hormone replacement therapy.
Somekawa Y; Wakabayashi A
Eur J Obstet Gynecol Reprod Biol; 1998 Aug; 79(2):185-91. PubMed ID: 9720839
[TBL] [Abstract][Full Text] [Related]
14. Increased frequencies of apolipoprotein epsilon 2 and epsilon 4 alleles in patients with ischemic heart disease.
Eto M; Watanabe K; Makino I
Clin Genet; 1989 Sep; 36(3):183-8. PubMed ID: 2791332
[TBL] [Abstract][Full Text] [Related]
15. Apo E variants in patients with type III hyperlipoproteinemia.
Civeira F; Pocoví M; Cenarro A; Casao E; Vilella E; Joven J; González J; Garcia-Otín AL; Ordovás JM
Atherosclerosis; 1996 Dec; 127(2):273-82. PubMed ID: 9125318
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E polymorphism influence on lipids, apolipoproteins and Lp(a) in a Spanish population underexpressing apo E4.
Muros M; Rodríguez-Ferrer C
Atherosclerosis; 1996 Mar; 121(1):13-21. PubMed ID: 8678918
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients.
Watanabe J; Kobayashi K; Umeda F; Yamauchi T; Mimura K; Nakashima N; Masakado M; Hiramatsu S; Nawata H
Diabetes Res Clin Pract; 1993 Apr; 20(1):21-7. PubMed ID: 8344125
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia.
Havekes L; de Wit E; Leuven JG; Klasen E; Utermann G; Weber W; Beisiegel U
Hum Genet; 1986 Jun; 73(2):157-63. PubMed ID: 3721502
[TBL] [Abstract][Full Text] [Related]
19. Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype.
Rall SC; Weisgraber KH; Innerarity TL; Bersot TP; Mahley RW; Blum CB
J Clin Invest; 1983 Oct; 72(4):1288-97. PubMed ID: 6313758
[TBL] [Abstract][Full Text] [Related]
20. Expression of type III hyperlipoproteinemia in patients homozygous for apolipoprotein E-2 is modulated by lipoprotein lipase and postprandial hyperinsulinemia.
Brümmer D; Evans D; Berg D; Greten H; Beisiegel U; Mann WA
J Mol Med (Berl); 1998 Apr; 76(5):355-64. PubMed ID: 9587070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
